One-Time gene therapy could free hemophilia patients from frequent infusions
NCT ID NCT06224907
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a one-time gene therapy (valoctocogene roxaparvovec) in 6 Japanese men with severe hemophilia A. The goal is to help their bodies produce their own clotting factor, reducing or stopping the need for regular factor VIII infusions. Participants will be monitored for safety and changes in bleeding episodes over about a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asahikawa Medical University Hospital
Hokkaido, Asahikawa, 078-8510, Japan
-
Nagoya University Hospital
Aichi, Nagoya, 466-8560, Japan
-
Saitama Medical University Hospital
Saitama, Iruma-gun, 350-0495, Japan
-
Tokyo Medical University Hospital
Tokyo, Shinjuku-ku, 160-0023, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- Do newer hemophilia drugs protect joints better? study aims to find out
- New clotting factor aims to cut bleeding episodes in severe hemophilia a
- Newborn screening study aims to catch rare diseases at birth
- New clotting factor aims to stop bleeding in severe hemophilia a